Small Vessel Coronary Disease: Dr. Megaly Presents Treatment Modalities at CVI 2026

Dr. Michael Megaly delivered an invited lecture on treatment strategies for small vessel coronary artery disease at Cardiovascular Innovations (CVI 2026) in Denver, Colorado, in August 2026; the latest in a series of national faculty appearances addressing the technical and evidence-based challenges of complex coronary intervention.

Small vessel coronary artery disease remains one of the most common and least resolved problems in interventional cardiology. Dr. Megaly opened by drawing the distinction that drives everything downstream: a small vessel is not the same as an unimportant vessel. European revascularization guidance defines a small target as one in which at least 75% of the segment distal to the lesion measures under 2 mm in diameter, while the 2022 consensus statement sets the working threshold for trials and clinical practice at 2.5 mm or less, measured after adequate vasodilation and, ideally, with intracoronary imaging rather than angiographic eyeball estimation, which systematically undersizes.

The clinical stakes are established. Dr. Megaly reviewed DUTCH PEERS data showing a stepwise gradient in two-year target lesion failure by minimum target vessel size: 9.3% for vessels under 2.25 mm and 9.8% for those between 2.25 and 2.50 mm, compared with 5.0% and 5.9% in vessels at or above 2.50 mm and 3.00 mm, respectively (chi-square p = 0.009). Pooled BIOFLOW data reinforced that device selection matters disproportionately in this subgroup, a significant separation in cumulative hazard between stent platforms in small-vessel lesions (log-rank p = 0.009) that disappeared entirely in non-small-vessel lesions (p = 0.873).

Much of the lecture addressed the leave-nothing-behind rationale: avoiding permanent metal in vessels least tolerant of late lumen loss, preserving vasomotor function in an already diseased segment, shortening DAPT duration, and flattening the long-term adverse event curve. Dr. Megaly presented the ANDROMEDA individual patient-level meta-analysis of randomized trials comparing paclitaxel-coated balloons with drug-eluting stents in small vessel disease. At 36 months, MACE was 18.5% with PCB versus 24.5% with DES (multivariable mixed-effects HR 0.75, 95% CI 0.58–0.95, p = 0.022), while target lesion failure did not differ significantly (13.2% vs 15.5%; HR 0.87, 95% CI 0.63–1.20, p = 0.401). Critically, the stratified analysis showed the benefit was driven by comparison against first-generation DES (HR 0.60, 95% CI 0.39–0.91); against second-generation DES, outcomes were equivalent (HR 0.98, 95% CI 0.67–1.43).

Dr. Megaly closed on drug-eluting resorbable scaffolds, reviewing magnesium-based platforms and the mechanistic argument that magnesium alloy degradation carries anti-inflammatory properties, in contrast to the acidic microenvironment produced by PLLA resorption. He presented BIOMAG-I data demonstrating preserved vasomotor response to acetylcholine and nitroglycerin at 12 months across proximal, in-scaffold, and distal segments, with three-year target lesion failure of 3.5% (95% CI 1.3–9.0) and no scaffold thrombosis, target vessel MI, or cardiac death.

The practical message for the audience was that small vessel PCI is a decision point, not a default, one that turns on accurate sizing with intracoronary imaging, and on matching the modality to the vessel rather than to habit.

Megaly M. "Small vessel CAD treatment modalities." Invited lecture, Cardiovascular Innovations (CVI 2026). Denver, CO. August 2026.

Dr. Michael Megaly specializes in complex and high-risk coronary interventions, chronic total occlusion (CTO) PCI, surgical turn-downs, complex peripheral artery disease, and limb salvage at Integris Health Heart Hospital in Oklahoma City.